ERY 974Alternative Names: Anti glypican3/CD3 bispecific antibody; ERY974; T cell redirecting bispecific antibody - Chugai
Latest Information Update: 06 Oct 2016
At a glance
- Originator Chugai Pharmaceutical
- Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action CD3 antigen inhibitors; Glypican 3 inhibitors; Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours